MDMX

New Review Published “The role of MDM2 and MDM4 in breast cancer development and prevention”

Posted on

jmcb

Great news, we have had a co-author review published in the Journal of Molecular and Cellular Biology.

You can check out the full review here.

Abstract

The major cause of death from breast cancer is not the primary tumour, but relapsing, drug-resistant, metastatic disease. Identifying factors that contribute to aggressive cancer offers important leads for therapy. Inherent defense against carcinogens depends on the individual molecular make-up of each person. Important molecular determinants of these responses are under the control of the mouse double minute (MDM) family: comprised of the proteins MDM2 and MDM4. In normal, healthy adult cells, the MDM family functions to critically regulate measured, cellular responses to stress and subsequent recovery. Proper function of the MDM family is vital for normal breast development, but also for preserving genomic fidelity. The MDM family members are best characterized for their negative regulation of the major tumour suppressor p53 to modulate stress responses. Their impact on other cellular regulators is emerging. Inappropriately elevated protein levels of the MDM family are highly associated with an increased risk of cancer incidence. Exploration of the MDM family members as cancer therapeutic targets is relevant for designing tailored anti-cancer treatments, but successful approaches must strategically consider the impact on both the target cancer and adjacent healthy cells and tissues. This review focuses on recent findings pertaining to the role of the MDM family in normal and malignant breast cells.

New Publication: Clinical Overview of MDM2/X-Targeted Therapies

Posted on Updated on

Figure1

Great news, we have a new Mini-Review published in Frontiers Oncology entitledĀ “Clinical Overview of MDM2/X-Targeted Therapies“, which is apart of the Research TopicĀ Human tumor-derived p53 mutants: a growing family of oncoproteins

Here is a little snippet from the Abstract to wet your appetite!

MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation and inhibiting its transcriptional activity. Both MDM2 and MDMX function as powerful oncogenes and are commonly over-expressed in some cancers, including sarcoma (~20%) and breast cancer (~15%).

In this overview, we will review the current MDM2- and MDMX-targeted therapies in development, focusing particularly on compounds that have entered into early phase clinical trials. We will highlight the challenges pertaining to predictive biomarkers for and toxicities associated with these compounds, as well as identify potential combinatorial strategies to enhance its anti-cancer efficacy.

The article is Open Access, which means its free for everyone and anyone to read and download!

You can view and download it directly here [Link]